A5068192630- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Medical Imaging Techniques and Applications
- Functional Brain Connectivity Studies
- Neuroscience and Neuropharmacology Research
- Advanced MRI Techniques and Applications
- Advanced Neuroimaging Techniques and Applications
- Neurotransmitter Receptor Influence on Behavior
- Neuroinflammation and Neurodegeneration Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Lanthanide and Transition Metal Complexes
- Receptor Mechanisms and Signaling
- Neurological Disease Mechanisms and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Radiopharmaceutical Chemistry and Applications
- Tryptophan and brain disorders
- Cerebrovascular and Carotid Artery Diseases
- Treatment of Major Depression
- Neuropeptides and Animal Physiology
- Health, Environment, Cognitive Aging
- Cholinesterase and Neurodegenerative Diseases
- Glioma Diagnosis and Treatment
- S100 Proteins and Annexins
- Stress Responses and Cortisol
University of Pittsburgh
2016-2025
UPMC Health System
2024
Florey Institute of Neuroscience and Mental Health
2023
The University of Melbourne
2023
Austin Health
2023
CSIRO Health and Biosecurity
2023
Centre for Addiction and Mental Health
2023
Johns Hopkins University
2006-2020
University of Florida
2020
Neurological Surgery
2020
This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared controls, typically showed marked retention PIB areas association cortex known to contain large amounts amyloid deposits AD. In patient group, was increased most prominently frontal (1.94-fold, p = 0.0001). Large increases also were observed parietal (1.71-fold, 0.0002), temporal...
Objective: To characterize the prevalence of amyloid deposition in a clinically unimpaired elderly population, as assessed by Pittsburgh Compound B (PiB) positron emission tomography (PET) imaging, and its relationship to cognitive function, measured with battery neuropsychological tests.Design: Subjects underwent testing PiB PET imaging (15 mCi for 90 minutes an ECAT HRϩ scanner).Logan graphical analysis was applied estimate regional retention distribution volume, normalized cerebellar...
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to β-pleated sheet aggregates of the amyloid-β (Aβ) peptide in vitro. vivo retention PiB brains people Alzheimer's disease shows a regional distribution that is very similar Aβ deposits observed post-mortem. However, basis for variations binding vivo, and extent which it different types Aβ-containing plaques tau-containing neurofibrillary tangles (NFT), has not been thoroughly...
A valid quantitative imaging method for the measurement of amyloid deposition in humans could improve Alzheimer's disease (AD) diagnosis and antiamyloid therapy assessment. Our group developed Pittsburgh Compound-B (PIB), an amyloid-binding radiotracer, positron emission tomography (PET). The current study was aimed to further validate PIB PET through (arterial input) inclusion subjects with mild cognitive impairment (MCI). studies were performed five AD, MCI, control retested within 20...
<h3>Background</h3> Pathology reports have shown that cholinergic forebrain neuronal losses in parkinsonian dementia (PDem) are equal to or greater than those Alzheimer disease (AD). We hypothesized patients with PDem would deficits were similar of AD. <h3>Objective</h3> To determine vivo cortical acetylcholinesterase (AChE) activity healthy control subjects and mild AD, PDem, Parkinson without using AChE positron emission tomography. <h3>Setting</h3> University Veterans' Administration...
The amyloid cascade hypothesis suggests that the aggregation and deposition of amyloid-β protein is an initiating event in Alzheimer9s disease (AD). Using imaging technology, such as positron emission tomography (PET) agent Pittsburgh compound-B (PiB), it possible to explore natural history preclinical people at high risk for AD. With this goal mind, asymptomatic (<i>n</i> = 5) symptomatic carriers presenilin-1 (PS1) mutations (C410Y or A426P) lead early-onset AD noncarrier controls from...
During the development of in vivo amyloid imaging agents, an effort was made to use micro-positron emission tomography (PET) presenilin-1 (PS1)/amyloid precursor protein (APP) transgenic mouse model CNS deposition screen new compounds and further study Pittsburgh Compound-B (PIB), a PET tracer that has been shown be retained well amyloid-containing areas Alzheimer's disease (AD) brain. Unexpectedly, we saw no significant retention PIB this even at 12 months age when PS1/APP typically exceeds...
Abstract Background Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) radiotracer in positron emission tomography (PET). Variability related to these factors contributes disagreement lack replicability research clinical trials. To address problems promote Aβ PET harmonization, we used [ 18 F]florbetaben (FBB) F]florbetapir (FBP) data from the Alzheimer’s Disease Neuroimaging...
Trials to test new drugs currently in development against tuberculosis humans are impractical. All animal models prioritize regimens imperfect, but nonhuman primates (NHPs) infected with Mycobacterium develop active (TB) disease a full spectrum of lesion types seen humans. Serial 2-deoxy-2-[18F]-fluoro-d-glucose (FDG) positron emission tomography (PET) computed (CT) imaging was performed on cynomolgus macaques during infection and chemotherapy individual agents or the four-drug combination...
<h3>Background</h3> Alzheimer disease (AD) is defined neuropathologically by the presence of neurofibrillary tangles and plaques associated with tau β-amyloid protein deposition. The colocalization microglia has been widely reported in pathological examination AD suggests that neuroinflammation may play a role pathogenesis and/or progression. Because postmortem histopathological analyses are limited to single end-stage assessment, time course nature this relationship not well understood....
Tau PET tracers exhibit varying levels of specific signal and distinct off-target binding patterns that are more diverse than amyloid tracers. This study compared 2 frequently used tau tracers, <sup>18</sup>F-flortaucipir <sup>18</sup>F-MK-6240, in the same subjects. <b>Methods:</b><sup>18</sup>F-flortaucipir <sup>18</sup>F-MK-6240 scans were collected within mo 15 elderly subjects clinical diagnosis cognition. FreeSurfer, version 5.3, was applied to 3-T MR images segment Braak pathologic...
<b>Background:</b> Reactive gliosis changes, characterized by reactive astrocytes and activated microglia, contribute greatly to neurodegeneration throughout the course of Alzheimer's disease (AD). overexpress monoamine oxidase-B (MAO-B). We clinical performance <sup>18</sup>F-SMBT-1, a novel MAO-B PET tracer as potential surrogate marker astrogliosis. <b>Methods:</b> Seventy-seven participants –53 controls (CN), 7 mild cognitively impaired (MCI), AD patients, 10 young (YCN)– were recruited...
Recently, an increasing number of tau tracers have become available. There is a need to standardize quantitative measures across tracers, supporting universal scale. We developed several cortical masks and applied them generate imaging scale.One thousand forty-five participants underwent scans with either 18F-flortaucipir, 18F-MK6240, 18F-PI2620, 18F-PM-PBB3, 18F-GTP1, or 18F-RO948. The mask was generated from cognitively unimpaired amyloid beta (Aβ)- subjects Alzheimer's disease (AD)...
Abstract INTRODUCTION Tau‐positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instrumentation, and methods analysis. METHODS Using head‐to‐head from five cohorts tau PET radiotracers designed target deposition AD, we tested a joint propagation model (JPM) harmonize quantification (units termed “CenTauR” [CTR]). JPM is statistical...
Abstract Positron emission tomography (PET) imaging of tau aggregation in Alzheimer’s disease (AD) is helping to map and quantify the vivo progression AD pathology. To date, no high-affinity tau-PET radiopharmaceutical has been optimized for non-AD tauopathies. Here we show properties analogues a first-in-class 4R-tau lead, [ 18 F]OXD-2115, using ligand-based design. Over 150 OXD-2115 were synthesized screened post-mortem brain tissue affinity against 3 H]OXD-2115, silico models used predict...
To determine whether there are abnormalities in the vivo status of serotonin type 2A (5-HT2A) receptor late-life depression and Alzheimer's disease, authors used positron emission tomography (PET) to assess patients with these two conditions healthy subjects.PET was performed by using [18F]altanserin evaluate 5-HT2A binding 11 elderly (four men, seven women; mean age = 65.0 years, SD 5.5); nine disease patients, including three concurrent (two 69.7 5.0); 10 age-matched subjects six 69.8...
There is increasing evidence for an empiric link between late-life depression and Alzheimer disease (AD). The neuropathology of AD, previously only confirmed at autopsy, may now be detectable in vivo using selective imaging ligands β-amyloid. Positron emission tomography (PET) with [11C] 6-OH-BTA-1 [Pittsburgh Compound-B (PiB)] has shown high tracer retention cortical areas patients clinical diagnoses probable AD low age-matched controls. We also reported variable PiB mild cognitive...